Caris Life Sciences study identifies clinically significant gene fusions in over 34,000 tumors
CAI•Caris Life Sciences announced two studies presented at the Association for Molecular Pathology’s 2026 annual meeting. Patients with novel ALK or FGFR2 fusions had survival comparable to patients with established fusions when treated with matched tyrosine kinase inhibitors, while a separate study identified rare PAK-family fusions in gynecologic serous cancers.
1. Study findings
Caris Life Sciences announced two studies presented at the Association for Molecular Pathology’s 2026 annual meeting. Patients with novel ALK or FGFR2 fusions who received matched tyrosine kinase inhibitors had survival comparable to patients with established fusions, and both groups survived longer than patients receiving treatments other than tyrosine kinase inhibitors.
2. Other gene fusions
A separate study identified rare PAK-family gene fusions in gynecologic serous cancers, potentially informing future targeted-therapy research.




